Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study
- 19 September 2013
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 14 (11), 1129-1140
- https://doi.org/10.1016/s1470-2045(13)70398-x
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Pomalidomide: First Global ApprovalDrugs, 2013
- Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomibBlood, 2013
- Carfilzomib: A Second-Generation Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple MyelomaAnnals of Pharmacotherapy, 2013
- An Open-Label Single-Arm Pilot Phase II Study (PX-171-003-A0) of Low-Dose, Single-Agent Carfilzomib in Patients With Relapsed and Refractory Multiple MyelomaClinical Lymphoma Myeloma and Leukemia, 2012
- Management of Relapsed and Relapsed/Refractory Multiple MyelomaJournal of the National Comprehensive Cancer Network, 2011
- Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapyCancer Letters, 2008
- FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell LymphomaThe Oncologist, 2007
- Clinical Experience With Intravenous and Oral Formulations of the Novel Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid in Patients With Advanced Hematologic MalignanciesJournal of Clinical Oncology, 2006
- Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced CancerJournal of Clinical Oncology, 2005
- Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implicationsProceedings of the National Academy of Sciences, 2003